Personalised cancer follow-up: risk stratification, needs assessment or both?

por Filleron, T, Dalenc, F, Kramar, A
Publicado 2012

Multistage designs for phase II clinical trials: statistical issues in cancer research.

por Kramar, A., Potvin, D., Hill, C.
Publicado 1996

Competing risks determining event-free survival in early breast cancer.

por Arriagada, R., Rutqvist, L. E., Kramar, A., Johansson, H.
Publicado 1992

Clinical Significance and Prognostic Value of CA72-4 Compared with CEA and CA19-9 in Patients with Gastric Cancer

por Ychou, M., Duffour, J., Kramar, A., Gourgou, S., Grenier, J.
Publicado 2000

Possible cohort effects in studies on oral contraceptive use and breast cancer.

por Lê, M. G., Hill, C., Kramar, A., Moulton, L. H.
Publicado 1985

Immunocytochemical assessment of sigma-1 receptor and human sterol isomerase in breast cancer and their relationship with a series of prognostic factors

por Simony-Lafontaine, J, Esslimani, M, Bribes, E, Gourgou, S, Lequeux, N, Lavail, R, Grenier, J, Kramar, A, Casellas, P
Publicado 2000

Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer

por Azria, D, Larbouret, C, Garambois, V, Kramar, A, Martineau, P, Robert, B, Aillères, N, Ychou, M, Dubois, J B, Pèlegrin, A
Publicado 2003

Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients

por Azria, D, Gourgou, S, Sozzi, W J, Zouhair, A, Mirimanoff, R O, Kramar, A, Lemanski, C, Dubois, J B, Romieu, G, Pelegrin, A, Ozsahin, M
Publicado 2004

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin

por Ploquin, A, Olmos, D, Lacombe, D, A'Hern, R, Duhamel, A, Twelves, C, Marsoni, S, Morales-Barrera, R, Soria, J-C, Verweij, J, Voest, E E, Schöffski, P, Schellens, J H, Kramar, A, Kristeleit, R S, Arkenau, H-T, Kaye, S B, Penel, N
Publicado 2012